Raf-1 kinase regulates smooth muscle contraction in the rat mesenteric arteries

Journal of Vascular Research

Volumn 47, Issue 5, 2010, Pages 384-398

  Sathishkumar, Kunju ^a   Yallampalli, Uma ^a   Elkins, Rebekah ^a   Yallampalli, Chandra ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Agonists; Blood pressure; Contraction; Extracellular signal regulated kinase; Intracellular calcium; Mitogen activated protein kinase; Protein kinase C; Raf 1; Vascular smooth muscle

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ANGIOTENSIN II; CALCIUM ION; ENDOTHELIN 1; ENZYME INHIBITOR; FURA 2; L 779450; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN BINDING PROTEIN C; MYOSIN LIGHT CHAIN; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PHENYLEPHRINE; PHORBOL DIBUTYRATE; POTASSIUM CHLORIDE; RAF PROTEIN; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE TONE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; CALCIUM; FEMALE; INDOLES; MESENTERIC ARTERIES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE CONTRACTION; MYOSIN LIGHT CHAINS; PHENOLS; PHENYLEPHRINE; PHORBOL 12,13-DIBUTYRATE; PROTEIN PHOSPHATASE 1; PROTO-ONCOGENE PROTEINS C-RAF; RATS; RATS, SPRAGUE-DAWLEY;

EID: 75149191458     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277726     Document Type: Article

References (49)

1. Berridge MJ: Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315-325.
2. Nishizuka Y: Turnover of inositol phospholipids and signal transduction. Science 1984; 225:1365-1370.
3. Tong XK, Hamel E: Transforming growth factor-|31 impairs endothelin-1-mediated contraction of brain vessels by inducing mi-togen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol Pharmacol 2007; 72: 1476-1483.
4. Komers R, Schutzer W, Xue H, Oyama TT, Lindsley JN, Anderson S: Effects of p38 mi-togen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Transl Res 2007; 150:343-349.
5. 2+ sensitization in rat ileal longitudinal smooth muscle. Am J Physiol Gastrointest Liver Physiol 2007; 293:G699-G710.
6. Tsai MH, Jiang MJ: Extracellular signal-regulated kinase1/2 in contraction of vascular smooth muscle. Life Sci 2005; 76: 877-888.
7. Xiao D, Zhang L: ERK MAP kinases regulate smooth muscle contraction in ovine uterine artery: effect of pregnancy. Am J Physiol Heart Circ Physiol 2002; 282:H292-H300.
8. Luo G, Jamali R, Cao YX, Edvinsson L, Xu CB: Vascular endothelin ET(B) receptor-mediated contraction requires phosphorylation of ERK1/2 proteins. Eur J Pharmacol 2006; 538: 124-131.
9. Ginnan R, Guikema BJ, Singer HA, Jourd'heuil D: PKC-8 mediates activation of ERK1/2 and induction of iNOS by IL-10 in vascular smooth muscle cells. Am J Physiol Cell Physiol 2006; 290:C1583-C1591.
10. Ginnan R, Singer HA: PKC-8-dependent pathways contribute to PDGF-stimulated ERK1/2 activation in vascular smooth muscle. Am J Physiol Cell Physiol 2005; 288: C1193-C1201.
11. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351: 289-305.
12. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Aikawa R Takano H, Yazaki Y: Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α1- and β-adrenoceptors. Circulation 1997; 95: 1260-1268.
13. Kim N, Kim H, Youm JB, Park WS, Warda M, Ko JH, Han J: Site specific differential activation of ras/raf/ERK signaling in rabbit isoproterenol-induced left ventricular hypertrophy. Biochim Biophys Acta 2006; 1763: 1067-1075.
14. Guerra B, Diaz M, Alonso R, Marin R: Plasma membrane oestrogen receptor mediates neuroprotection against |3-amyloid toxicity through activation of Raf-1/MEK/ERK cascade in septal-derived cholinergic SN56 cells. J Neurochem 2004; 91: 99-109.
15. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC: The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 2004; 23:3061-3071.
16. DeChant AK, Dee K, Weyman CM: Raf-in-duced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase 3 activation. Oncogene 2002; 21: 5268-5279.
17. Samuel DS, Ewton DZ, Coolican SA, Petley TD, McWade FJ, Florini JR: Raf-1 activation stimulates proliferation and inhibits IGF-stimulated differentiation in L6A1 myoblasts. Horm Metab Res 1999; 31: 55-64.
18. Yogi A, Callera GE, Montezano AC, Aranha AB, Tostes RC, Schiffrin EL, Touyz RM: En-dothelin-1, but not Ang II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007; 27: 1960-1967.
19. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, Cheng TH: Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004; 61:159-168.
20. Krepinsky JC, Li Y, Tang D, Liu L, Scholey J, Ingram AJ: Stretch-induced Raf-1 activation in mesangial cells requires actin cytoskeletal integrity. Cell Signal 2005; 17:311-320.
21. Liao DF, Duff JL, Daum G, Pelech SL, Berk BC: Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells, Role of Raf. Circ Res 1996; 79: 1007-1014.
22. Baccarini M: An old kinase on a new path: Raf and apoptosis. Cell Death Differ 2002; 9: 783-785.
23. Hindley A, Kolch W: Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 2002; 115: 1575-1581.
24. Janosch P, Kieser A, Eulitz M, Lovric J, Sauer G, Reichert M, Gounari F, Buscher D, Baccarini M, Mischak H, Kolch W: The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. FASEB J 2000; 14: 2008-2021.
25. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, Baccarini M: Raf-1-as-sociated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 2000; 275:22300-22304.
26. Broustas CG, Grammatikakis N, Eto M, Dent P, Brautigan DL, Kasid U: Phosphoryla-tion of the myosin-binding subunit of myo-sin phosphatase by Raf-1 and inhibition of phosphatase activity. J Biol Chem 2002; 277: 3053-3059.
27. 2+ sensitivity in vascular smooth muscle. J Smooth Muscle Res 2004; 40: 219-236.
28. Alessi D, MacDougall LK, Sola MM, Ikebe M, Cohen P: The control of protein phospha-tase-1 by targetting subunits. The major my-osin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Eur J Biochem 1992; 210:1023-1035.
29. Hartshorne DJ: Myosin phosphatase: sub-units and interactions. Acta Physiol Scand 1998; 164:483-493.
30. 2+ sensitization of myosin light chain phosphorylation in smooth muscle. Biochem J 1996; 31 8: 469-475.
31. 2-contraction in pregnant rat mesenteric ar ter y. J Vasc Res 2008; 45: 33-44.
32. Schumacher C, Cioffi CL, Sharif H, Haston W, Monia BP, Wennogle L: Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications. Mol Pharmacol 1998; 53:97-104.
33. Abe JI, Che W, Yoshizumi M, Huang Q, Glassman M, Ohta S, Wu Y, Arlinghaus R, Berk BC: Bcr in vascular smooth muscle cells involvement of Ras and Raf-1 activation by Bcr. Ann NY Acad Sci 2001; 947:341-343.
34. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sam-mani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG: Genomic assessment of a multi-kinase inhibitor, sorafenib, in a rodent model of pulmonary hy per tension. Physiol Genomics 20 08; 33: 278-291.
35. Yue X, Varga EV, Stropova D, Vanderah TW, Yamamura HI, Roeske WR: Chronic morphine-mediated adenylyl cyclase superacti-vation is attenuated by the Raf-1 inhibitor, GW5074. Eur J Pharmacol 2006; 540:57-59.
36. Varga EV, Rubenzik M, Grife V, Sugiyama M, Stropova D, Roeske WR, Yamamura HI: Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. Eur J Pharmacol 2002; 451: 101-102.
37. Yue X, Varga EV, Stropova D, Vanderah TW, Yamamura HI, Roeske WR: Chronic morphine-mediated adenylyl cyclase superacti-vation is attenuated by the Raf-1 inhibitor, GW5074. Eur J Pharmacol 2006; 540:57-59.
38. Watanabe T, Pakala R, Katagiri T, Benedict CR: Serotonin potentiates angiotensin II-in-duced vascular smooth muscle cell proliferation. Atherosclerosis 2001; 159:269-279. (Pubitemid 33127240)
39. 2+ influx. Endocrinology 1999; 140: 1385-1391.
40. Webb ML, Taylor DS, Molloy CJ: Effects of thrombin receptor activating peptide on phosphoinositide hydrolysis and protein kinase C activation in cultured rat aortic smooth muscle cells: evidence for 'tethered-ligand' activation of smooth muscle cell thrombin receptors. Biochem Pharmacol 1993; 45: 1577-1582.
41. Baldassare JJ, Henderson PA, Fisher GJ: Plasma membrane associated phospholipase C from human platelets: synergistic stimulation of phosphatidylinositol 4,5-bisphos-phate hydrolysis by thrombin and guanosine 5'-O-(3-thiotriphosphate). Biochemistry 1989; 28:56-60.
42. Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 1998; 280:109-112.
43. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ, Kuppuswamy D: c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 2002; 277: 23065-23075.
44. Budzyn K, Paull M, Marley PD, Sobey CG: Segmental differences in the roles of rho-ki-nase and protein kinase C in mediating va-soconstriction. J Pharmacol Exp Ther 2006; 317: 791-796.
45. Chen DB, Davis JS: Epidermal growth factor induces c-fos and c-jun mRNA via Raf-1/MEK1/ERK-dependent and-independent pathways in bovine luteal cells. Mol Cell En-docrinol 2003; 200: 14 1-1 5 4.
46. Chin PC, Liu L, Morrison BE, Siddiq A, Ratan RR, Bottiglieri T, D'Mello SR: The c-Raf inhibitor GW5074 provides neuropro-tection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neuro-chem 2004; 90: 595-608.
47. Maioli E, Torricelli C, Fortino V: Functional interactions of protein kinase A and C in signalling networks: a recapitulation. Cell Mol Life Sci 2006; 63: 637-641.
48. Kartha S, Naureckas ET, Li J, Hershenson MB: Partial characterization of a novel mito-gen-activated protein kinase/extracellular signal-regulated kinase activator in airway smooth-muscle cells. Am J Respir Cell Mol Biol 1999; 20: 1041-1048.
49. Monick MM, Carter AB, Flaherty DM, Peterson MW, Hunninghake GW: Protein ki-nase C zeta plays a central role in activation of the p42/44 mitogen-activated protein ki-nase by endotoxin in alveolar macrophages. J Immunol 200 0; 16 5: 4632-4639.